Merck & Co. Inc. (MRK)

The market has largely priced in the 2028 Keytruda patent cliff, with Merck trading at a discount reflecting aggressive revenue erosion assumptions. Merck is actively expanding in oncology, immunology...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced the presentation of new oncology data across more than 12 tumor types at the 2025 American Society...

Merck & Co. is undervalued, trading at lower multiples than peers, due to concerns over patent expirations and recent financial volatility. Despite modest overall revenue growth, oncology—especially K...

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference.

DARMSTADT, Germany--(BUSINESS WIRE)--Not intended for UK-, US- or Canada-based media Merck, a leading science and technology company, today announced positive data on enpatoran, an investigational, or...

The IDeate-Esophageal01 study is set to evaluate Merck & Daiichi's ADC drug ifinatamab deruxtecan in pre-treated patients with esophageal squamous cell carcinoma.

I'm targeting value in overlooked sectors, highlighting Merck and Federal Realty as top picks for income and upside potential. Merck offers a low 8.5x PE, a 4.3% yield, a robust drug pipeline, and res...

There are over 12,000 publicly traded stocks in the United States; not even the most intelligent investors with the best tools can immediately find them. Many investors and traders typically maintain ...

Both PFE and MRK have strong product and pipeline portfolios in oncology.